Patents by Inventor Michal Galezowski

Michal Galezowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Urea derivatives and methods of use thereof
    Patent number: 11345669
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 31, 2022
    Assignee: NodThera Limited
    Inventors: David Harrison, Alan Paul Watt, Nicolas Boutard, Charles-Henry Fabritius, Michal Galezowski, Piotr Kowalczyk, Oleksandr Levenets, Jakub Woyciechowski
  • IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR
    Publication number: 20200369665
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers, isotopologues, or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer, isotopologues, or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: June 29, 2018
    Publication date: November 26, 2020
    Applicant: RYVU THERAPEUTICS S.A.
    Inventors: Aneta BOBOWSKA (NÉE WITKOWSKA), Michal GALEZOWSKI, Mateusz NOWAK, Claude COMMANDEUR, Joanna SZEREMETA-SPISAK, Marcin NOWOGRODZKI, Alicja OBARA, Anna DZIELAK, Iwona LOZINSKA, Marcelina DUDEK (NÉE SEDLAK), Anita ` JANIGA, Jacek REUS, Marek WRONOWSKI, Magdalena ZASTAWNA, Adam RADZIMIERSKI, Mateusz SWIRSKI, Julian ZACHMANN, Charles-Henry FABRITIUS, Roderick Alan PORTER, Joanna FOGT
  • CHEMICAL COMPOUNDS
    Publication number: 20200131141
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: March 12, 2018
    Publication date: April 30, 2020
    Inventors: David HARRISON, Alan Paul WATT, Nicolas BOUTARD, Charles-Henry FABRITIUS, Michal GALEZOWSKI, Piotr KOWALCZYK, Oleksandr LEVENETS, Jakub WOYCIECHOWSKI
  • Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases
    Patent number: 10577365
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 3, 2020
    Assignees: Felicitex Therapeutics, Inc., Selvita S.A.
    Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
  • Benzimidazole derivatives as kinase inhibitors
    Patent number: 10174013
    Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 8, 2019
    Assignee: SELVITA S.A.
    Inventors: Wojciech Czardybon, Krzysztof Brzózka, Michal Galezowski, Renata Windak, Mariusz Milik, Magdalena Zawadzka, Pawel Guzik, Ewelina Wincza, Marta Prokop, Katarzyna Wiklik, Aleksandra Sabiniarz, Wieslaw Marek Cholody, Raymond Horvath, Tomasz Rzymski
  • PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
    Publication number: 20180305331
    Abstract: Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.
    Type: Application
    Filed: October 20, 2016
    Publication date: October 25, 2018
    Applicant: SELVITA S.A.
    Inventors: Tomasz RZYMSKI, Mariusz MILIK, Krzysztof BRZOZKA, Charles-Henry FABRITIUS, Katarzyna KUCWAJ-BRYSZ, Urszula KULESZA, Ewelina WINCZA, Agnieszka DREAS, Michal GALEZOWSKI
  • PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS
    Publication number: 20180265467
    Abstract: The present invention relates to pyrazolidine derivatives and related compounds, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of such compounds and pharmaceutical compositions for the prophylaxis and treatment of medical conditions that can be affected by inhibiting lactate dehydrogenase (LDH), in particular LDHA and/or LDHB.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 20, 2018
    Applicant: SELVITA S.A.
    Inventors: Michal GALEZOWSKI, Andrzej GONDELA, Oleksandr LEVENETS, Joanna FOGT, Lukasz DUDEK, Alicja OBARA, Jakub WOYCIECHOWSKI, Marta SOWINSKA, Marcin KROL, Artur BIELA, Tomasz RSYMSKI
  • DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES
    Publication number: 20180179199
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 20, 2017
    Publication date: June 28, 2018
    Applicants: Felicitex Therapeutics, Inc., Selvita S.A.
    Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
  • Substituted tricyclic benzimidazoles as kinase inhibitors
    Patent number: 9745299
    Abstract: Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: August 29, 2017
    Assignee: SELVITA SA
    Inventors: Tomasz Rzymski, Adrian Zarebski, Agnieszka Dreas, Karolina Osowska, Katarzyna Kucwaj, Joanna Fogt, Marek Cholody, Michal Galezowski, Wojciech Czardybon, Raymond Horvath, Katarzyna Wiklik, Mariusz Milik, Krzysztof Brzózka
  • NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20170152249
    Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 1, 2017
    Inventors: Wojciech CZARDYBON, Krzysztof Brzózka, Michal Galezowski, Renata Windak, Mariusz Milik, Magdalena Zawadzka, Pawel Guzik, Ewelina Wincza, Marta Prokop, Katarzyna Wiklik, Aleksandra Sabiniarz, Wieslaw Marek Cholody, Raymond Horvath, Tomasz Rzymski
  • Benzimidazole derivatives as Kinase Inhibitors
    Patent number: 9388192
    Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 12, 2016
    Assignee: Selvita S.A.
    Inventors: Wojciech Czardybon, Krzysztof Brzózka, Michal Galezowski, Renata Windak, Mariusz Milik, Magdalena Zawadzka, Pawel Guzik, Ewelina Wincza, Marta Prokop, Katarzyna Wiklik, Aleksandra Sabiniarz, Wieslaw Marek Cholody, Raymond Horvath, Tomasz Rzymski
  • PYRIDINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS
    Publication number: 20160009697
    Abstract: Compounds of formula (I), wherein X, Y, Z, R1-R7, m and n are as defined herein, exhibit 5-HT6 antagonistic activity and are thus useful for the treatment of certain CNS disorders. Methods of use of said compounds are also provided.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 14, 2016
    Inventors: Charles-Henry FABRITIUS, Michal GALEZOWSKI, Marcin KROL, Mateusz NOWAK
  • Novel Benzimidazole Derivatives as Kinase Inhibitors
    Publication number: 20150336967
    Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 26, 2015
    Inventors: Wojciech CZARDYBON, Kraków BRZÓZKA, Michal GALEZOWSKI, Renata WINDAK, Mariusz MILIK, Magdalena ZAWADZKA, Pawel GUZIK, Ewelina WINCZA, Marta PROKOP, Katarzyna WIKLIK, Aleksandra SABINIARZ, Wieslaw Marek CHOLODY, Raymond HORVATH, Tomasz RZYMSKI
  • SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS
    Publication number: 20150274726
    Abstract: Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 1, 2015
    Inventors: Tomasz Rzymski, Adrian Zarebski, Agnieszka Dreas, Karolina Osowska, Katarzyna Kucwaj, Joanna Fogt, Marek Cholody, Michal Galezowski, Wojciech Czardybon, Raymond Horvath, Katarzyna Wiklik, Mariusz Milik, Krzysztof Brzózka